Reports Q3 revenue $45.9M, consensus $47.97M. The company reported $456.1M in cash, cash equivalents and investments, which it expects to fund the company to profitability. “The third quarter was another remarkable period of commercial and pipeline execution for Syndax (SNDX). Demand remained strong for Revuforj and Niktimvo with over $75M in combined net sales for the quarter,” said Michael Metzger, CEO. “We also furthered our leadership in menin inhibition with the addition of Revuforj to the NCCN Guidelines for R/R NPM1m AML in late September followed by FDA approval in late October. Our expansion into this second indication is underway and we are making great progress driving awareness and generating demand. Additionally, we continue to advance the development of both Revuforj and Niktimvo in the frontline setting, further unlocking their multi-billion-dollar potential.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Syndax options imply 10.9% move in share price post-earnings
- Syndax announces Revuforj, Niktimvo data accepted for presentation at ASH 2025
- SNDX Upcoming Earnings Report: What to Expect?
- Syndax Pharmaceuticals Launches Promising Phase 3 AML Study with Revumenib
- Syndax Pharmaceuticals’ Revumenib Study: A Potential Game-Changer in Leukemia Treatment